Sunday sees the start of TCT2013, probably the most important annual event when it comes to discussing minimally invasive cardiac interventions. St. Jude Medical, Inc., has chosen to preview its presence at the event with the announcement that it has gained U.S. FDA approval of its ILUMIEN™ OPTIS™ PCI Optimization™ System, a new technology designed to provide physicians with a comprehensive disease assessment tool for treating patients with coronary artery disease (CAD). The system, first introduced in Europe back in May 2013 will see its US launch at the event.
St.Jude says its ILUMIEN platform helps physicians better understand which arteries should be treated and how best to treat them. It works by integrating both Fractional Flow Reserve (FFR) technology to measure blood flow blockage inside the coronary arteries and intravascular Optical Coherence Tomography (OCT) imaging technology.
The OCT imaging technology provides a real-time, three-dimensional (3-D) reconstruction of the patient’s vessel, making it easier for physicians to visualize the area they are treating. The new system offers twice the resolution of the earlier generation, which allows for better microscopic examination of disease inside the artery to assist with stent placement. St. Jude Medical is the only company to have these tools available in an integrated platform.
“The ILUMIEN OPTIS is an advancement that offers an eye-opening perspective of the coronary arteries, providing me with a more complete understanding about the extent of the patient’s disease,” said Dr. Matthew J. Price, Director of the Cardiac Catheterization Laboratory at Scripps Green Hospital/Scripps Clinic in La Jolla, California. “The high-definition, three-dimensional format and the new stent placement tools allow me to create a treatment plan tailored for each patient’s unique vasculature — and to confirm that I get the best possible stent result. That makes my life easier and helps the patient, too.”
“The advancements in the ILUMIEN OPTIS system continue to build on St. Jude Medical’s leadership in providing innovative products that reduce health care costs and improve outcomes for patients battling coronary artery disease. This next-generation system is a scientific advancement that delivers critical information to physicians about the location and severity of disease within the coronary arteries, potentially resulting in better medical decision-making and overall cost-effective treatment,” said Frank J. Callaghan, president of the St. Jude Medical Cardiovascular and Ablation Technologies Division.
Full press release here.
Image provided courtesy of St. Jude Medical, Inc
Source: St.Jude Medical, Inc., Businesswire